244 related articles for article (PubMed ID: 37093359)
21. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
22. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
23. Safety of fecal microbiota, live-jslm (REBYOTA
Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
[TBL] [Abstract][Full Text] [Related]
24. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
25. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Berenson CS; Lashner B; Korman LY; Hohmann E; Deshpande A; Louie TJ; Sims M; Pardi D; Kraft CS; Wang EEL; Cohen SH; Feuerstadt P; Oneto C; Misra B; Pullman J; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L; Lee CH
Clin Infect Dis; 2023 Nov; 77(11):1504-1510. PubMed ID: 37539715
[TBL] [Abstract][Full Text] [Related]
27. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
[TBL] [Abstract][Full Text] [Related]
28. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent
Abdali ZI; Roberts TE; Barton P; Hawkey PM
EClinicalMedicine; 2020 Jul; 24():100420. PubMed ID: 32637898
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection.
Xuan S; Zangwill KM; Ni W; Ma J; Hay JW
J Gen Intern Med; 2020 Apr; 35(4):1102-1110. PubMed ID: 32016703
[TBL] [Abstract][Full Text] [Related]
31. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
J Clin Gastroenterol; 2023 Nov; ():. PubMed ID: 38019088
[TBL] [Abstract][Full Text] [Related]
32. Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.
Bouza E; Cobo J; Rodríguez-Hernández MJ; Salavert M; Horcajada JP; Iribarren JA; Obi E; Lozano V; Maratia S; Cuesta M; Uría E; Limón E
Rev Esp Quimioter; 2021 Apr; 34(2):126-135. PubMed ID: 33618513
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Kyle Jensen M; LaFleur J; Nelson RE
Infect Control Hosp Epidemiol; 2015 Apr; 36(4):438-44. PubMed ID: 25782899
[TBL] [Abstract][Full Text] [Related]
34. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
Stallhofer J; Steube A; Katzer K; Stallmach A
Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
[TBL] [Abstract][Full Text] [Related]
35. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
[TBL] [Abstract][Full Text] [Related]
36. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
Luo Y; Lucas AL; Grinspan AM
Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
[TBL] [Abstract][Full Text] [Related]
38. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.
Lee CH; Chai J; Hammond K; Jeon SR; Patel Y; Goldeh C; Kim P
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1731-1735. PubMed ID: 31165961
[TBL] [Abstract][Full Text] [Related]
39. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
